Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Why Novartis Is Still A 'Buy' After 15% Surge
10:45am, Sunday, 13'th Jul 2025
Despite Trump's hot take toward the pharmaceutical industry and his hard stance on U.S. trading partners, Novartis' share price continues to rise. The main contributors to maintaining bullish sentimen
Novartis loses bid to block US Entresto generic through 2026
12:27pm, Friday, 11'th Jul 2025
Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto through late 2026, a Delaware federal judge said on Friday.
Why Novartis (NVS) is a Top Value Stock for the Long-Term
10:40am, Tuesday, 08'th Jul 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis gets approval for first malaria drug for babies and children
01:36am, Tuesday, 08'th Jul 2025
Novartis on Tuesday said it had received approval in Switzerland for Coartem, which it said was the first drug to treat malaria in babies and young children.
Novartis receives approval for first malaria medicine for newborn babies and young infants
01:15am, Tuesday, 08'th Jul 2025
Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatmen
Here's Why Novartis (NVS) is a Strong Momentum Stock
10:55am, Monday, 07'th Jul 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study
11:35am, Thursday, 03'rd Jul 2025
NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.
Novartis drug Cosentyx fails late-stage trial for artery disease
01:42am, Thursday, 03'rd Jul 2025
Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the arteries.
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
01:25am, Thursday, 03'rd Jul 2025
The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
01:15am, Thursday, 03'rd Jul 2025
Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteriti
Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July Start
10:46am, Wednesday, 02'nd Jul 2025
As Wall Street faces mixed moves in July, NVS, ALG, MT, BILI and STRL stand out as low-leverage stocks to weather volatility.
Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?
10:15am, Tuesday, 01'st Jul 2025
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
7 Killer European Stocks To Buy In July
10:52am, Sunday, 29'th Jun 2025
As you look at the stock markets around the world, it's always a balance of trying to decide when is the right time to buy.
Final Trades: Novartis, Sixth Street, Amazon and the IYF
01:22pm, Thursday, 26'th Jun 2025
The Investment Committee give you their top stocks to watch for the second half.
ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target
